Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I listened to the call and what I saw was an arrogant CEO will does not really care about his shareholders. In short, I think he lied about the trials. To publicly state several rimes 3 trials will start and then just decide it was not worth it to update shareholders is a lie. This CEO is a liar.
Boy aren't you the optimist. LOL!
Maybe it is time to give the SEC a call and discuss an investigation into AVXL to see if this is a big scam. I contacted an attorney yesterday that specializes in securities litigation and he suggested I start there. I explained the lack of news from the CEO and he responded and said that is not illegal. But if the CEO had made several commitments to start trials and people bought stock based on this, then he is now in a clear violation of SEC rules. He said notifying the SEC can't hurt. I see class actions starting again.
Same answer he gave me. The answer is vague and covers his ass in case things change. guidance is a vague term in this environment. I think Dr. Missling overrated and was way too aggressive. It is December 7th and still not one word. I do not believe that they will start any trials at this point.
And let's say all three are announced and start. What does start mean? Does start mean signing up patients, or does it mean submitting the paperwork? With 25 dayshift i believe symantics will play a roll in the news announcements. Yes we started and are filling out the paperwork. I really hope that is not the case, but with absolutely no news, I assume this possibility.
I have emailed and spoken to Clayton twice. I know for a fact he is traveling this week and will not be back in the office until Wednesday. But if you email him, he responds pretty quickly. This is the new IR department for Anavex. They started this past summer.
Sorry to disagree and this is just my opinion but Missling is the one that said 3 trials would start in 2017. And now it is December 4th and no news. I am not one bit optimistic a trial will start now in 2017. But being transparent would go along way. If the trials are going to be held up because of an FDA process delay, than tell your shareholders. It is pretty easy. Stock is going down even without news.
JMHO!
Missing knows that shareholders are becoming more and more impatient. I spoke with the IR person and he stated that. So knowing that he knows how longtime shareholders feel, why can'y he put out a simple update on the trials? Is it better to stay silent for your shareholders, or is it better to stay silent for your own personnel reputation. I think at this point, silence is not good either way.
Your right that would be sweet music to my ears. We can always hope.
What does that have to do with Anavex announcing the three trials. Everyone is waiting for Dr. Missling to update on the trials and spell out some details. Funding or no funding, Dr. Missling needs to make an important shareholder announcement. Everything else I am reading on the hub board is very good reading, but means nothing without trials. We need to start these trials.
There is so much (call it what you want) speculation about the upcoming three trials that it has now piled up so high we cannot see the sunrise or sunsets anymore. Today is December 1st and there is still no news. Patience has now turned into concern. AS we go through the month with no news concern will turn into doubt. Saying this, many will hold hope. Isn't that what many would call insanity? Sorry, but as I sit here and have owned this stock for 2 years, I am down 30% on my investment and we are no further along with this drug. Just sayin!
I have spoken to Clayton real time before. This group took over all IR functions for Anavex. His response is real and anyone can call himeto discuss. I put his contact info on the post. Obviously we all know that anything can happen and at this point he has confirmed that Anavex plans to initiate all three as stated. GLTA!
All, here is a response from Clayton Robertson an associate with the The Trout Group LLC which is the IR group for AVXL.
GM Clayton, I recently asked this question at the beginning of November and you had responded that Dr. Missling and team still plan to start the three trials in 2017. I believe the three trials are Rhetts, Parkinson's and ALZ. I is now the end of November or essentially beginning of the last month of 2017 and there has been no news at all. Can you tell me what the current status is? Do they still plan to start all three trials in 2017, or a subset of the three?
His response to me.
That is correct. All three trials to be initiated, guidance hasn't changed.
Out of office today and tomorrow, but can call you next week. Anyone can contact him. I got the response this morning.
Clayton Robertson
Associate
The Trout Group LLC
740 Broadway, 9th Floor
New York, NY 10003
+1 646 378 2964 Direct
+1 646 323 3950 Cell
+1 646 378 2901 Fax
crobertson@troutgroup.com
www.troutgroup.com
we need more than hope. We need trial start dates , preferable in 2017.
Xena, do you still believe the trials to start in 2017? If so, why? If not why?
What would I do if i sold on 11/30 and on 12/1 no news came out and the stock price went to $3/share.
Keeping all the information from shareholders is a bad sign, period. dr. Missling tells the shareholders nothing about what this company is doing. That is not a good sign. I am here until the end of Nov 2017. After that if there is no news, I am out.
I spoke to a live person at The Trout Group who confirmed all three trials would start this year and confirmed Missling is still planning all three trials. It appears that AVXL now uses The Trout Group for all investor relations questions. But he confirmed the start of all three trials.
Doesn't the FDA have to approve as well.
I feel violated today. The last couple days has been just awful.
https://insiderfinancial.com/anavex-life-sciences-corp-nasdaqavxl-is-an-undervalued-alzheimers-play
Insider Financial. Read the article. news is getting out.
I found an article yesterday that said that Missling had an Investor call yesterday morning to discuss the recent data. Apparently news is getting out now. We are up this morning in pre market.
Thank you for that post. I read 100 or sophists so far and all I see is scientist pontificating over the data. You are spot on. The data was good and in the next 45 days we will get updates on other data and trials. I see $15/share by end of year.
Bourbon, if all comes true and we are at $15/share end of year, I will be one happy guy. Question; Why are none of these presentations on their website for October?
A scientific response to your post. Bra Bla Blq Bla Bla. The fact is, we have had no news at all about any trial, any data, anything at all. Everything on this board that people post is "assumptions" based on lack of information. AVXL/Missling is treating shareholders like the distance friends. This sucks and we need news on when these trials will start and updated data that was promised.
I have to reply to your post. I read the posts from many on iHub and it is apparent that no one on these messages knows anything. There are so many assumptions it is ridiculous. And the one about' we should hear something in a few weeks" is pathetic. Missing is hiding information from shareholders and all the people on this board have no idea what he is doing.
This CEO is either very incompetent or extremely sly (conman). OMG! where's the beef!
Investor2014, my assumptions are that he is holding onto information that is due his shareholders. If he had info that the data was bad and could adversely affect the stock price and held this date for months, he is in a clear SEC violation. I have asked several lawyers who have a firm grasp on the rules. So my assumption right now is the data is good if not great and he is holding off for other reasons and these will help shareholders.
Call me naive, but we all have to assume the best right now.
Turner2017, There has been a lot of talk about BIIB buying AVXL. My question has been and will be until proof is shown of success is, why would BIIB buy any company including AVXL with out solid Data on 273 that says, we are successful. Right now there is nothing. maybe AVXL/Missling has great Data to share, but he has not today. I like you numbers, but BIIB would not pay that much for a dream.
Thanks Bourbon. Always bringing common sense to this board. Not to say others do not, but you seem to have a very good grasp on this "investment". Go AVXL!
KITE does not have $2Billion in revenue. Where do you see this?
Good Day, thanks for that info. Do I assume that the PTO will issue 09/05/2017. And that the PTO will issue the publication on 10/02/2017.
Really, so if Biogen offered 1/2 as ideal you would not take it. $284/share. I 'll take it.
I can tell you one thing for sure, if Missling has a report that clearly shows bad data and has not released it i.e. hiding info from shareholders, the SEC will come after him and the board. I doubt very seriously that he is holding bad info back. There is another good reason for why he has not shared that data. Could it be related to this article about Biogen?
https://finance.yahoo.com/news/todays-research-reports-stocks-watch-121000413.html
So based on what I read, the original deal was Roche bout a piece of the pie and finally bought the rest at $95/share. So those shareholders made out big time.
Amer to that brother.
The author of that article is clueless. Wrote the article because his boss Adam told him too write it. Sad bunch of people.
Did anyone see that Dr. Missling filed a form 4 and issued himself another 450K shares. I wonder why at this time? maybe something is up.
Tom Skarpelos
Mr. Skarpelos, a director of Anavex, is a self-employed investor with 17 years of experience working with private and public companies. For the past 10 years, he has been focused on biotechnology companies involved in drug discovery and drug development projects.Mr. Skarpelos was engaged as a consultant to Anavex Life Sciences for one year effective August 2, 2010. His experience has led to relationships with researchers at academic institutes in Europe and North America. Mr. Skarpelos is a founder of Anavex Life Sciences, and is its largest shareholder.
I thought Missling was the largest shareholder. I guess I was wrong. Thanks for posting the link.
wow, very interesting. It looks like Biogen has a lot of pressure unit's executives.
Knoll Capital owns 724,000 shares or 1.78% of total outstanding shares. Still a lot, but not the 5% that would be needed to file with the SEC.
here is what I think will happen with the preferred shares. JMO! There is a large Pharma who is very interested in a deal with AVXL. Using the preferred shares, AVXL can raise a bunch of money by selling these shares to the Pharma at a price, most likely far above the current price. I believe AVXL held back the 15 month info well knowing once they release it, the stock will move north. Again, just my opinion. However, preferred shares can be used to raise money and give the company much needed flexibility as opposed to bonds. JMHO! We are north of $10/shares by end of April.